Stemline Therapeutics Reports Third Quarter 2019 Financial Results
07 nov. 2019 16h57 HE
|
Stemline Therapeutics, Inc.
Net revenue for ELZONRIS® was $13.3 million for the third quarterNew patient starts estimated to have increased greater than 20% from last quarterConference call and live webcast scheduled for...
Stemline Therapeutics Announces Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming ASH Meeting
06 nov. 2019 09h15 HE
|
Stemline Therapeutics, Inc.
NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Stemline Therapeutics to Host Conference Call on Third Quarter 2019 Financial Results on November 8, 2019
05 nov. 2019 16h22 HE
|
Stemline Therapeutics, Inc.
NEW YORK, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Stemline Therapeutics Announces ELZONRIS® Clinical Data Selected for Oral Presentation at the 81st Annual Meeting of the Japanese Society of Hematology
08 oct. 2019 07h30 HE
|
Stemline Therapeutics, Inc.
NEW YORK, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Stemline Therapeutics Recaps Felezonexor (SL-801) Clinical Data Presentation From ESMO 2019 Congress
01 oct. 2019 07h30 HE
|
Stemline Therapeutics, Inc.
NEW YORK, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Stemline Therapeutics Announces Felezonexor (SL-801) Clinical Data to be Featured at Upcoming ESMO 2019 Congress
27 sept. 2019 07h30 HE
|
Stemline Therapeutics, Inc.
NEW YORK, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Stemline Therapeutics to Present at the 2019 Cantor Global Healthcare Conference
26 sept. 2019 16h01 HE
|
Stemline Therapeutics, Inc.
NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Stemline Therapeutics to Present at the Ladenburg Thalmann 2019 Healthcare Conference
18 sept. 2019 09h32 HE
|
Stemline Therapeutics, Inc.
NEW YORK, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Stemline Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference
05 sept. 2019 07h30 HE
|
Stemline Therapeutics, Inc.
NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Stemline Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference
09 août 2019 16h00 HE
|
Stemline Therapeutics, Inc.
NEW YORK, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...